Genetic counseling

Thirteen Ovation Research Abstracts Accepted for Presentation at ASRM 2021

Thursday, October 21, 2021 - 8:00am

Nashville, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Ovation Fertility teams are presenting three oral presentations and 10 poster presentations at the 2021 ASRM Scientific Congress & Expo, which takes place both virtually and in-personin Baltimore October 17-20, 2021.

Key Points: 
  • Nashville, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Ovation Fertility teams are presenting three oral presentations and 10 poster presentations at the 2021 ASRM Scientific Congress & Expo, which takes place both virtually and in-personin Baltimore October 17-20, 2021.
  • Additionally, Ovation scientists are leading interactive sessions and roundtable discussions at the annual event, where top experts in reproductive medicine discuss the latest in reproductive care.
  • The list of Ovation abstracts and presentations accepted for ASRM 2021 covers a wide range of groundbreaking findings in the fields of IVF, genetic testing, and the use of artificial intelligence in embryo selection.
  • Ovation also helps IVF labs across America improve their quality and performance with expert off-site lab direction and consultation.

Advancements in reproductive medicine available at Shady Grove Fertility (SGF) can reduce the inheritance of genetic diseases like breast cancer

Thursday, October 14, 2021 - 1:45pm

Individuals and couples with known genetic diseases can turn to Shady Grove Fertility (SGF) to undergo in vitro fertilization (IVF) with preimplantation genetic testing for monogenic/single gene defects(PGT-M) to reduce the risk of passing genetic mutations to future offspring.

Key Points: 
  • Individuals and couples with known genetic diseases can turn to Shady Grove Fertility (SGF) to undergo in vitro fertilization (IVF) with preimplantation genetic testing for monogenic/single gene defects(PGT-M) to reduce the risk of passing genetic mutations to future offspring.
  • Additionally, patients at risk for dominant gene mutations, such as breast cancer or inherited forms of colon cancer, can have individualized testing for these diseases.
  • While Rose is not a carrier for the breast cancer gene, she is a carrier of a rare X-linked genetic mutation called Wiskott-Aldrich syndrome.
  • We are so fortunate to live in a world where we can now reduce the inheritance of deadly genetic diseases via IVF.

Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients

Monday, October 11, 2021 - 7:35pm

There is a misconception that genetic testing is only useful as a preventative tool prior to a cancer diagnosis.

Key Points: 
  • There is a misconception that genetic testing is only useful as a preventative tool prior to a cancer diagnosis.
  • However, genetic testing can provide insights that can help inform and refine precision therapy use and clinical treatment trial enrollment.
  • In addition, genetic testing results can be used to help prevent recurrence and reduce incidence of other inherited cancers.
  • The collaboration with Invitae expands access to genetic testing, a vitally important tool in the patients cancer care arsenal.

JScreen.org Adds CancerGEN to National Genetic Screening Program Just in Time for Cancer Awareness Months This Fall

Wednesday, October 6, 2021 - 3:01pm

This not-for-profit home education and genetic screeningprogramstarted in 2013 with reproductive genetic testing called ReproGEN, and now tests for risk for over 40 types of hereditary cancer with the addition of the CancerGEN test.

Key Points: 
  • This not-for-profit home education and genetic screeningprogramstarted in 2013 with reproductive genetic testing called ReproGEN, and now tests for risk for over 40 types of hereditary cancer with the addition of the CancerGEN test.
  • "Making cancer genetic testing accessible is key," said Jane Lowe Meisel, MD, Associate Professor of Hematology and Medical Oncology at Emory University School of Medicine, and medical director for JScreen's cancer program.
  • "Launching our new cancer program and providing convenient and affordable access to cancer genetic testing across the US will help save lives."
  • JScreen believes the combination of education, access to premier genetic screening technologies and personalized, confidential support are the keys to preventing devastating diseases.

Veritas Intercontinental completes its perinatal services offering with the launch of myPrenatalWES, an innovative prenatal diagnostic test

Wednesday, September 29, 2021 - 1:57pm

MADRID, Sept. 29, 2021 /PRNewswire/ -- Veritas Intercontinental launches myPrenatalWES, a differential prenatal diagnostic test developed for at-risk pregnancies that provides, with a single technique, an analysis of deletions and duplications (CNVs or Copy Number Variants) along with the molecular study of genes related to fetal findings.

Key Points: 
  • - Veritas Intercontinental expands its range of perinatal services with the launch of myPrenatalWES, an innovative prenatal diagnostic test indicated for pregnancies with risk of genetic alteration.
  • - myPrenatalWES technology is a breakthrough because it allows, with a single test, to replace the different techniques used in prenatal diagnosis, shortening the response time, and maximizing the diagnostic yield.
  • -Veritas opened its state-of-the-art genetics laboratory in 2020, offering perinatal services to its global partners.
  • In the absence of findings, a second technique of sequencing of specific genes related to the ultrasound findings is necessary.

Veritas Intercontinental completes its perinatal services offering with the launch of myPrenatalWES, an innovative prenatal diagnostic test

Wednesday, September 29, 2021 - 1:55pm

MADRID, Sept. 29, 2021 /PRNewswire/ -- Veritas Intercontinental launches myPrenatalWES, a differential prenatal diagnostic test developed for at-risk pregnancies that provides, with a single technique, an analysis of deletions and duplications (CNVs or Copy Number Variants) along with the molecular study of genes related to fetal findings.

Key Points: 
  • - Veritas Intercontinental expands its range of perinatal services with the launch of myPrenatalWES, an innovative prenatal diagnostic test indicated for pregnancies with risk of genetic alteration.
  • - myPrenatalWES technology is a breakthrough because it allows, with a single test, to replace the different techniques used in prenatal diagnosis, shortening the response time, and maximizing the diagnostic yield.
  • -Veritas opened its state-of-the-art genetics laboratory in 2020, offering perinatal services to its global partners.
  • In the absence of findings, a second technique of sequencing of specific genes related to the ultrasound findings is necessary.

Bipartisan Cancer Patient Equity Act (CPEA 2021) H.R.5377 Introduced by Rep. Butterfield (D-NC-01) and Rep. Bilirakis (R-FL-12): Advocacy Campaign Success of SHEPHERD Foundation on Behalf of Rare Cancer Patients

Tuesday, September 28, 2021 - 7:32pm

If passed, the Act will expand coverage for cancer molecular analysis and testing and encourage education and awareness.

Key Points: 
  • If passed, the Act will expand coverage for cancer molecular analysis and testing and encourage education and awareness.
  • Too often patients do not have access to these tests unless their cancer reoccurs, at which point it may be too late.
  • Through SHEPHERD Therapeutics and the SHEPHERD Foundation, we attack rare cancer from every angle, with the goal of saving millions of lives.
  • The SHEPHERD Foundation is a non-profit fighting to generate industry-wide change related to rare cancer awareness and therapeutic availability.

New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients

Saturday, September 25, 2021 - 5:15pm

This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs.

Key Points: 
  • This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs.
  • Notably, the research found that a change in clinical management once genetic results were received was reported by clinicians for nearly half of patients.
  • The full research presentation from Invitae included:
    Epilepsy genetic testing guides clinical management and helps improve patient outcomes.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the findings and implications of the study; and the value of genetic testing to guide clinical management and improve outcomes for epilepsy patients.

Phosphorus CEO Alex Bisignano to Speak at Precision Medicine World Conference on Impact of Population Genetic Screening

Thursday, September 23, 2021 - 2:00pm

The Precision Medicine World Conference brings together leaders from biotechnology, medicine, social sciences, big data, and other key fields to catalyze initiatives in precision medicine.

Key Points: 
  • The Precision Medicine World Conference brings together leaders from biotechnology, medicine, social sciences, big data, and other key fields to catalyze initiatives in precision medicine.
  • GeneCompass is available on the Phosphorus website for $249, a price point on par with consumer genetic ancestry tests.
  • Phosphorus' mission is to extend and improve lives by making genomics a foundational part of everyone's health and wellness journey.
  • Additionally, Phosphorus provides white-labeling genomics-as-a-service solutions by partnering with organizations who want to deploy their own preventative genetic testing solutions.

Parkinson's Foundation Presents Six Studies at MDS Virtual Congress 2021

Wednesday, September 22, 2021 - 1:55pm

MIAMIand NEW YORK, Sept. 22, 2021 /PRNewswire/ -- The Parkinson's Foundation presented six scientific posters highlighting research, care and education at the MDS Virtual Congress 2021 hosted by the International Parkinson and Movement Disorders Society.

Key Points: 
  • MIAMIand NEW YORK, Sept. 22, 2021 /PRNewswire/ -- The Parkinson's Foundation presented six scientific posters highlighting research, care and education at the MDS Virtual Congress 2021 hosted by the International Parkinson and Movement Disorders Society.
  • A pilot project aims to determine the feasibility of a Parkinson's Foundation accreditation for PD exercise education programs.
  • The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure.
  • Since 1957, the Parkinson's Foundation has invested more than $400 million in Parkinson's research and clinical care.